UBS Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31M | Buy |
+157,200
| New | +$30.3M | ﹤0.01% | 2134 |
|
|
2025
Q2 | – | Sell |
-20,000
| Closed | -$2.94M | – | 10241 |
|
|
2025
Q1 | $2.94M | Sell |
20,000
-41,250
| -67% | -$5.97M | ﹤0.01% | 4335 |
|
|
2024
Q4 | $8.03M | Buy |
61,250
+11,250
| +23% | +$1.57M | ﹤0.01% | 3305 |
|
|
2024
Q3 | $7.79M | Sell |
50,000
-38,700
| -44% | -$6.25M | ﹤0.01% | 2618 |
|
|
2024
Q2 | $13.8M | Sell |
88,700
-51,300
| -37% | -$7.72M | ﹤0.01% | 1973 |
|
|
2024
Q1 | $19M | Buy |
140,000
+75,550
| +117% | +$10M | ﹤0.01% | 1738 |
|
|
2023
Q4 | $8.68M | Hold |
64,450
| – | – | ﹤0.01% | 2218 |
|
|
2023
Q3 | $8.73M | Sell |
64,450
-186,600
| -74% | -$25.5M | ﹤0.01% | 2088 |
|
|
2023
Q2 | $35.9M | Buy |
251,050
+1,200
| +0.5% | +$177K | 0.01% | 1012 |
|
|
2023
Q1 | $34.7M | Buy |
249,850
+247,000
| +8,667% | +$33.2M | 0.01% | 998 |
|
|
2022
Q4 | $386K | Hold |
2,850
| – | – | ﹤0.01% | 4920 |
|
|
2022
Q3 | $313K | Buy |
2,850
+500
| +21% | +$63.4K | ﹤0.01% | 4739 |
|
|
2022
Q2 | $311K | Sell |
2,350
-105,000
| -98% | -$13.8M | ﹤0.01% | 4608 |
|
|
2022
Q1 | $14.2M | Buy |
107,350
+97,500
| +990% | +$11.7M | ﹤0.01% | 1677 |
|
|
2021
Q4 | $1.15M | Hold |
9,850
| – | – | ﹤0.01% | 4259 |
|
|
2021
Q3 | $1.18M | Hold |
9,850
| – | – | ﹤0.01% | 4039 |
|
|
2021
Q2 | $1.18M | Buy |
9,850
+7,500
| +319% | +$823K | ﹤0.01% | 4036 |
|
|
2021
Q1 | $234K | Sell |
2,350
-450
| -16% | -$45.2K | ﹤0.01% | 5367 |
|
|
2020
Q4 | $280K | Hold |
2,800
| – | – | ﹤0.01% | 5013 |
|
|
2020
Q3 | $307K | Buy |
2,800
+800
| +40% | +$89K | ﹤0.01% | 4533 |
|
|
2020
Q2 | $212K | Buy |
2,000
+1,600
| +400% | +$165K | ﹤0.01% | 4763 |
|
|
2020
Q1 | $36K | Buy |
+400
| New | +$37.7K | ﹤0.01% | 6076 |
|
|
2019
Q4 | – | Sell |
-500
| Closed | -$45K | – | 8097 |
|
|
2019
Q3 | $45K | Sell |
500
-16,100
| -97% | -$1.4M | ﹤0.01% | 6254 |
|
|
2019
Q2 | $1.37M | Sell |
16,600
-29,200
| -64% | -$2.29M | ﹤0.01% | 3481 |
|
|
2019
Q1 | $3.7M | Buy |
45,800
+22,150
| +94% | +$1.75M | ﹤0.01% | 2454 |
|
|
2018
Q4 | $1.8M | Buy |
23,650
+450
| +2% | +$35.1K | ﹤0.01% | 3137 |
|
|
2018
Q3 | $1.84M | Sell |
23,200
-4,900
| -17% | -$371K | ﹤0.01% | 3289 |
|
|
2018
Q2 | $1.97M | Buy |
28,100
+3,550
| +14% | +$255K | ﹤0.01% | 3185 |
|
|
2018
Q1 | $1.72M | Sell |
24,550
-31,000
| -56% | -$2.15M | ﹤0.01% | 3257 |
|
|
2017
Q4 | $3.85M | Buy |
55,550
+2,300
| +4% | +$155K | ﹤0.01% | 2610 |
|
|
2017
Q3 | $3.61M | Buy |
53,250
+15,700
| +42% | +$992K | ﹤0.01% | 2542 |
|
|
2017
Q2 | $2.56M | Buy |
37,550
+800
| +2% | +$52.2K | ﹤0.01% | 2779 |
|
|
2017
Q1 | $2.29M | Buy |
36,750
+35,700
| +3,400% | +$2.08M | ﹤0.01% | 2829 |
|
|
2016
Q4 | $57K | Buy |
1,050
+750
| +250% | +$42.6K | ﹤0.01% | 5717 |
|
|
2016
Q3 | $20K | Sell |
300
-500
| -63% | -$32.7K | ﹤0.01% | 6281 |
|
|
2016
Q2 | $48K | Hold |
800
| – | – | ﹤0.01% | 5548 |
|
|
2016
Q1 | $45K | Sell |
800
-300
| -27% | -$18K | ﹤0.01% | 5584 |
|
|
2015
Q4 | $75K | Sell |
1,100
-500
| -31% | -$32.8K | ﹤0.01% | 5450 |
|
|
2015
Q3 | $102K | Sell |
1,600
-200
| -11% | -$13.2K | ﹤0.01% | 5220 |
|
|
2015
Q2 | $115K | Buy |
1,800
+100
| +6% | +$6.85K | ﹤0.01% | 5290 |
|
|
2015
Q1 | $116K | Sell |
1,700
-27,700
| -94% | -$1.92M | ﹤0.01% | 5297 |
|
|
2014
Q4 | $2.07M | Buy |
+29,400
| New | +$2.11M | ﹤0.01% | 2874 |
|
Other funds holding AZN
IA
VCM
VAM
UBS Group's AZN Position: Q1 2026 in Review
UBS Group increased its AstraZeneca (AZN) stake by 316% in Q1 2026, buying an estimated $876M and bringing the position to 5,981,411 shares worth $1.18B. The position accounts for 0.18% of the portfolio, ranked #107.
UBS Group first reported a position in AZN in Q4 2014 and has held it in 46 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- UBS Group held 5,981,411 shares of AstraZeneca worth $1.18B as of Q1 2026.
- UBS Group bought 4,542,013 AstraZeneca shares in Q1 2026, an estimated $876M.
- AstraZeneca made up 0.18% of UBS Group's portfolio in Q1 2026, its #107 holding.
- UBS Group first reported a position in AstraZeneca in Q4 2014 and has held it in 46 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.